China's Ascentage Pharma targets $149 mln raise in US IPO
21/01/2025 11:13
Jan 21 (Reuters) - China-based Ascentage Pharma 6855.HK said on Tuesday it was targeting to raise $149 million in its initial public offering in the United States. (Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Shounak Dasgupta) ((ArasuKannagi.Basil@thomsonreuters.com))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up